Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-derived Xenograft Mouse Model
Journal of Visualized Experiments · 2023
DOI: 10.3791/64535 ↗Kurz gefasst
Video/Audio in der Zeitschrift Journal of Visualized Experiments, 2023. Verfasst von Claudia Manriquez Roman und 8 weiteren Autor:innen. Beteiligte Einrichtung: T Cell Engineering Laboratory, Mayo Clinic, Rochester; Division of Hematology, Mayo Clinic, Rochester; Mayo Clinic Graduate School of Biomedical Scie…. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Chimeric antigen receptor T (CART) cell therapy has emerged as a powerful tool for the treatment of multiple types of CD19+ malignancies, which has led to the recent FDA approval of several CD19-targeted CART (CART19) cell therapies. However, CART cell therapy is associated with a unique set of toxicities that carry their own morbidity and mortality. This includes cytokine release syndrome (CRS) and neuroinflammation (NI). The use of preclinical mouse models has been crucial in the research and development of CART technology for assessing both CART efficacy and CART toxicity. The available preclinical models to test this adoptive cellular immunotherapy include syngeneic, xenograft, transgenic, and humanized mouse models. There is no single model that seamlessly mirrors the human immune system, and each model has strengths and weaknesses. This methods paper aims to describe a patient-derived xenograft model using leukemic blasts from patients with acute lymphoblastic leukemia as a strategy to assess CART19-associated toxicities, CRS, and NI. This model has been shown to recapitulate CART19-associated toxicities as well as therapeutic efficacy as seen in the clinic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- T Cell Engineering Laboratory, Mayo Clinic, Rochester; Division of Hematology, Mayo Clinic, Rochester; Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester; Department of Molecular Medicine, Mayo C…
- T Cell Engineering Laboratory, Mayo Clinic, Rochester; Division of Hematology, Mayo Clinic, Rochester.
- Department of Immunology, Mayo Clinic, Rochester.
- T Cell Engineering Laboratory, Mayo Clinic, Rochester; Division of Hematology, Mayo Clinic, Rochester; Department of Immunology, Mayo Clinic, Rochester; Kenderian.saad@mayo.edu.
Förderung
- NCI NIH HHS
Zitieren
APA
Manriquez Roman, C., Sakemura, R. L., Kimball, B. L., Jin, F., Khadka, R. H., Adada, M. M., Siegler, E. L., Johnson, A. J., & Kenderian, S. S. (2023). Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-derived Xenograft Mouse Model. Journal of Visualized Experiments. https://doi.org/10.3791/64535
Vancouver
Manriquez Roman C, Sakemura RL, Kimball BL, Jin F, Khadka RH, Adada MM, et al. Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-derived Xenograft Mouse Model. Journal of Visualized Experiments. 2023. doi:10.3791/64535
BibTeX
@article{ManriquezRoman2023,
author = {Manriquez Roman, Claudia and Sakemura, R Leo and Kimball, Brooke L and Jin, Fang and Khadka, Roman H and Adada, Mohamad M and Siegler, Elizabeth L and Johnson, Aaron J and Kenderian, Saad S},
title = {Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-derived Xenograft Mouse Model},
journal = {Journal of Visualized Experiments},
year = {2023},
doi = {10.3791/64535}
}
EUVIMED